Compared to placebo, acamprosate increased the number of days drinkers stayed abstinent by about 11%, and reduced the odds of their return to drinking by 9% during a 3- to 12-month follow-up period. Combining naltrexone and acamprosate increased the odds of sobriety by 30% — but this drug cocktail had so many side effects that many patients simply dropped out.
Tuesday, September 14, 2010
Meta-analysis of acamprosate
Money quote:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment